Equities

Spruce Biosciences Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
SPRB:NAQ

Spruce Biosciences Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)52.62
  • Today's Change-0.86 / -1.61%
  • Shares traded40.00
  • 1 Year change+70.71%
  • Beta3.6885
Data delayed at least 15 minutes, as of Feb 19 2026 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2024202420232022
ASSETS
Cash And Short Term Investments399679
Total Receivables, Net------
Total Inventory------
Prepaid expenses3.183.883.32
Other current assets, total2.281.971.21
Total current assets4410284
Property, plant & equipment, net0.931.181.40
Goodwill, net------
Intangibles, net------
Long term investments----0
Note receivable - long term------
Other long term assets0.030.550.61
Total assets4510486
LIABILITIES
Accounts payable1.303.331.43
Accrued expenses12159.40
Notes payable/short-term debt000
Current portion long-term debt/capital leases1.621.621.62
Other current liabilities, total04.91--
Total current liabilities152412
Total long term debt0.121.723.29
Total debt1.753.344.92
Deferred income tax------
Minority interest------
Other liabilities, total1.021.261.42
Total liabilities162717
SHAREHOLDERS EQUITY
Common stock0.000.000.00
Additional paid-in capital279274218
Retained earnings (accumulated deficit)(250)(197)(149)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total--0(0.56)
Total equity297768
Total liabilities & shareholders' equity4510486
Total common shares outstanding0.560.550.31
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.